Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 3:56 AM
Ignite Modification Date: 2025-12-26 @ 2:47 AM
NCT ID: NCT03575702
Description: None
Frequency Threshold: 1
Time Frame: Up to 35 days after the end of treatment
Study: NCT03575702
Study Brief: Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Uritos® one tablet orally twice a day (after breakfast and dinner) for 12 weeks Uritos®: film-coated tablets 0.1 mg 0 None 0 149 70 149 View
Urotol® one tablet orally twice a day (after breakfast and dinner) for 12 weeks Urotol®: film coated tablets, 2 mg 0 None 0 150 72 150 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Dry mouth SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (20.1) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (20.1) View
Abdominal pain SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (20.1) View
Constipation SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (20.1) View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (20.1) View
Abdominal distension SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (20.1) View
Abdominal pain lower SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (20.1) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (20.1) View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (20.1) View
Dysgeusia SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (20.1) View
Somnolence SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (20.1) View
Rash SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (20.1) View
Respiratory tract infection viral SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (20.1) View
Asthenia SYSTEMATIC_ASSESSMENT General disorders MedDRA (20.1) View
Thirst SYSTEMATIC_ASSESSMENT General disorders MedDRA (20.1) View
Malaise SYSTEMATIC_ASSESSMENT General disorders MedDRA (20.1) View
Dry eye SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Vision blurred SYSTEMATIC_ASSESSMENT Eye disorders MedDRA (20.1) View
Dysuria SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA (20.1) View
Urinary retention SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA (20.1) View
Dry skin SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (20.1) View
Pruritus SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (20.1) View
Nasal dryness SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (20.1) View
Cough SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (20.1) View
Tachycardia SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA (20.1) View
Back pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (20.1) View
Hypertensive crisis SYSTEMATIC_ASSESSMENT Vascular disorders MedDRA (20.1) View
Hyperglycemia SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (20.1) View